Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma

Author:

Thomas Anne,Virdee Pradeep S.,Eatock Martin,Lord Simon R.,Falk Stephen,Anthoney D. Alan,Turkington Richard C.,Goff Matthew,Elhussein Leena,Collins Linda,Love Sharon,Moschandreas Joanna,Middleton Mark R.

Funder

AstraZeneca

Cancer Research UK

Experimental Cancer Medicine Centre

NIHR Clinical Research Network

Roche

GSK

Amgen

Novartis

Immunocore

BMS

Eisai

Merck

Rigontec

BiolineRx

Array Biopharma

Novartis,

Millennium

Vertex

Pfizer

Regeneron

TCBiopharma

Replimune

University of Oxford

National Institute for Health Research

Oxford Biomedical Research Centre

Leicester ECMC

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. CRUK. Cancer Statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/: [CRUK] .

2. Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037;Offman;Br J Canc,2018

3. Esophageal cancer: staging system and guidelines for staging and treatment;Berry;J Thorac Dis,2014

4. National Oesophago-gastric cancer audit,2018

5. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer;Allum;J Clin Oncol,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3